As of 2025-12-16, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -2.41. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 1,544.31 mil USD. RXRX's TTM EBITDA according to its financial statements is -640.05 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 15.1x | 13.6x |
| Forward P/E multiples | 15.5x - 21.8x | 18.6x |
| Fair Price | (17.86) - (17.36) | (18.66) |
| Upside | -525.1% - -513.4% | -544.2% |
| Date | EV/EBITDA |
| 2025-12-15 | -2.41 |
| 2025-12-12 | -2.52 |
| 2025-12-11 | -2.72 |
| 2025-12-10 | -2.88 |
| 2025-12-09 | -2.88 |
| 2025-12-08 | -2.92 |
| 2025-12-05 | -2.83 |
| 2025-12-04 | -3.00 |
| 2025-12-03 | -2.79 |
| 2025-12-02 | -2.51 |
| 2025-12-01 | -2.54 |
| 2025-11-28 | -2.76 |
| 2025-11-26 | -2.58 |
| 2025-11-25 | -2.55 |
| 2025-11-24 | -2.52 |
| 2025-11-21 | -2.39 |
| 2025-11-20 | -2.13 |
| 2025-11-19 | -2.27 |
| 2025-11-18 | -2.38 |
| 2025-11-17 | -2.35 |
| 2025-11-14 | -2.36 |
| 2025-11-13 | -2.52 |
| 2025-11-12 | -2.78 |
| 2025-11-11 | -2.83 |
| 2025-11-10 | -2.66 |
| 2025-11-07 | -2.75 |
| 2025-11-06 | -2.75 |
| 2025-11-05 | -3.03 |
| 2025-11-04 | -3.06 |
| 2025-11-03 | -3.42 |
| 2025-10-31 | -3.48 |
| 2025-10-30 | -3.59 |
| 2025-10-29 | -3.77 |
| 2025-10-28 | -3.80 |
| 2025-10-27 | -4.12 |
| 2025-10-24 | -3.91 |
| 2025-10-23 | -3.66 |
| 2025-10-22 | -3.67 |
| 2025-10-21 | -3.96 |
| 2025-10-20 | -4.43 |
| 2025-10-17 | -3.76 |
| 2025-10-16 | -4.17 |
| 2025-10-15 | -4.52 |
| 2025-10-14 | -3.79 |
| 2025-10-13 | -3.49 |
| 2025-10-10 | -3.32 |
| 2025-10-09 | -3.80 |
| 2025-10-08 | -3.95 |
| 2025-10-07 | -3.25 |
| 2025-10-06 | -3.49 |